Precision BioSciences (DTIL)
Develops ARCUS-based in vivo gene-editing therapies.
$6.76
vs last close−0.43 (−5.98%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 64.47% | 17.79M shares | |
|---|---|---|---|
| 98 holders · as of Jun 30, 2026 | |||
| Insiders | 2.93% | 808.2K shares | |
| 12 holders · as of Aug 3, 2026 | |||
| Strategic holders | 7.75% | 2.14M shares | |
| 1 holder · as of Jan 27, 2026 | |||
| Other | 24.85% | 6.86M shares | |
| remainder | |||
27.60M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (27.60M in the company's Sep 23, 2026 report, 12.83M elsewhere); stakes use the report.
13F, as of Jun 30, 2026
98 holders · 17.79M shares · 33 new positions · 65 increased · 14 reduced · 13 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Abrdn PLC | 2.23M | 8.08% | 0 | Jul 31, 2026 |
| Bleichroeder LP | 2.02M | 7.31% | +355.7K | Aug 13, 2026 |
| Octagon Capital Advisors LP | 1.35M | 4.89% | −886.7K | Aug 14, 2026 |
| Boothbay Fund Management, LLC | 1.35M | 4.88% | +280.0K | Aug 14, 2026 |
| BlackRock, Inc. | 1.17M | 4.25% | +973.1K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 1.12M | 4.04% | +205.5K | Aug 13, 2026 |
| LYNX1 Capital Management LP | 950.5K | 3.44% | −34.6K | Aug 13, 2026 |
| Driehaus Capital Management LLC | 946.7K | 3.43% | −48.7K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Octagon Capital Advisors LP | 9.99% | 2.33M | 13G | Feb 10, 2026 |
| Readout Capital, LP | 9.30% | 1.11M | 13G | Aug 14, 2025 |
| Aberdeen Group plc | 8.88% | 2.14M | 13G | Jan 27, 2026 |
| Bleichroeder LP | 8.21% | 1.90M | 13G | Feb 13, 2026 |
| Empery Asset Management, LP | 7.63% | 1.97M | 13G | Apr 15, 2026 |
| Lynx1 Capital Management LP | 5.40% | 1.39M | 13G | Jul 20, 2026 |
| Highbridge Capital Management, LLC | 5.30% | 406.3K | 13G | Nov 14, 2024 |
| Weinstein Benjamin | 5.20% | 395.5K | 13G | Mar 18, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Feb 18, 2026 | J. Jefferson Smithofficer: Chief Research Officer | Sale | 4,925 | $3.84 | 121,926 |
| Feb 18, 2026 | Dario Scimecaofficer: General Counsel and Secretary | Sale | 4,925 | $3.84 | 56,457 |
| Feb 18, 2026 | John Alexander Kellyofficer: Chief Financial Officer | Sale | 8,149 | $3.84 | 125,883 |
| Feb 18, 2026 | Michael Amorosodirector, officer: President and CEO | Sale | 20,559 | $3.84 | 243,392 |
| Jan 21, 2026 | J. Jefferson Smithofficer: Chief Research Officer | Sale | 10,200 | $4.03 | 110,184 |
| Jan 21, 2026 | John Alexander Kellyofficer: Chief Financial Officer | Sale | 15,213 | $4.03 | 106,448 |
| Jan 21, 2026 | Dario Scimecaofficer: General Counsel and Secretary | Sale | 8,854 | $4.03 | 44,715 |
| Jan 22, 2026 | Michael Amorosodirector, officer: President and CEO | Sale | 34,799 | $4.17 | 196,154 |
| Dec 15, 2025 | Melinda Browndirector | Purchase | 1,381 | $4.97 | 23,346 |
| Dec 16, 2025 | Stanley Frankeldirector | Purchase | 2,700 | $4.70 | 19,478 |
House and Senate disclosures
Not reported.